Anti-Aging
CJC-1295
CJC-1295 has limited clinical safety data. FDA reports potential immunogenicity and serious adverse events associated with its use.
At a glance
CJC-1295 has limited clinical safety data. FDA reports potential immunogenicity and serious adverse events associated with its use.
What is CJC-1295?
CJC-1295 is an experimental, long-acting analog of growth hormone-releasing hormone (GHRH). Its research purpose is to stimulate the body's release of growth hormone and increase insulin-like growth factor I (IGF-I). A change in a hormone measurement is not itself proof of improved health, strength, recovery, or lifespan.
This distinction matters because wellness marketing often translates a biological mechanism into promises about muscle gain, fat loss or rejuvenation. Those outcomes require their own controlled studies in the intended patient population; they cannot be assumed from hormone measurements in healthy volunteers.
Sources: [cjc-trial]
What the human research measured
A 2006 publication described two randomized, placebo-controlled, double-blind ascending-dose studies in healthy adults aged 21–61. The studies lasted 28 and 49 days and examined pharmacokinetics, hormone responses and safety rather than long-term anti-aging outcomes.
The investigators reported sustained increases in growth hormone and IGF-I, with an estimated half-life of 5.8–8.1 days for the studied compound. No serious adverse reactions were reported in those trials. These short studies do not establish long-term safety, safety in people with chronic disease, or benefits for athletic recovery.
A trial's reassuring tolerability findings and later regulatory safety concerns can coexist. They describe different evidence sets and may involve different exposures. Neither should be omitted when evaluating the overall uncertainty.
Sources: [cjc-trial]
With DAC, without DAC, and product identity
The long-acting formulation studied in the cited paper should not be treated as equivalent to every product labeled “CJC-1295 without DAC.” DAC refers to a drug-affinity complex. Commercial naming can obscure meaningful differences in the actual molecule and duration of exposure.
Ask for the exact substance, formulation and supporting study rather than relying on a shorthand name. A half-life measured for one formulation cannot establish a dosing schedule for another. This guide does not provide dosing, cycling or injection instructions.
Sources: [cjc-trial] [fda-safety]
FDA safety concerns and approval context
FDA reports limited clinical data for CJC-1295 and identifies potential immunogenicity and peptide-related impurity concerns. It also reports serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reactions.
A compounding nomination or a seller's availability claim is not an FDA determination that a treatment is safe and effective. The FDA source cited here is a safety assessment, not an approved prescribing label or an endorsement of anti-aging use.
Sources: [fda-safety]
Combinations and questions for a clinician
Marketing frequently pairs CJC-1295 with ipamorelin. The cited CJC-1295 studies do not establish the safety or effectiveness of that combination. Effects of two substances cannot be assumed to add predictably, and the absence of a listed interaction does not prove that a combination is safe.
Ask which evidence supports the proposed clinical goal, whether the studied formulation matches the offered product, and how adverse effects would be assessed. Symptoms attributed to “low hormones” deserve clinical evaluation rather than self-treatment based on an online protocol.
Sources: [fda-safety] [cjc-trial]
Frequently asked questions
These FAQs use the sources listed below. They are not independently clinically reviewed.
What's the difference between CJC-1295 with and without DAC?
Products marketed with and without a drug-affinity complex (DAC) should not be assumed interchangeable. Marketing terminology is not enough to identify a formulation or establish a safe schedule. FDA reports limited clinical data and adverse events including increased heart rate and systemic vasodilatory reactions for CJC-1295.
Sources: [fda-safety]
Sources and reading notes
Sources support the cited sections or FAQs, not every statement in a legacy overview. A source link is not an endorsement of a product or treatment.
[fda-safety] U.S. Food and Drug Administration — Compounding substances that may present significant safety risks
Substance-specific safety concerns; inclusion or removal from a compounding list is not marketing approval.
[cjc-trial] Peer-reviewed journal / PubMed — Teichman et al. (2006): CJC-1295 in healthy adults
About this entry
Article updated: .
AI-assisted source synthesis prepared for Peptide Directory. No independent clinical review has been performed.